Stock CONCORD6 CONCORD DRUGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Concord Drugs Limited

Equities

CONCORD6

INE858L01010

Delayed Bombay S.E.
Other stock markets
 02:55:30 2024-07-01 EDT 		5-day change 1st Jan Change
38.9 INR +0.03% Intraday chart for Concord Drugs Limited +0.05% -34.86%
05-30 Concord Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
03-19 Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Concord Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
CI
Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer
CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Concord Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023
CI
Concord Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023
CI
Concord Drugs Eyes INR 207 Million Rights Issue
MT
Concord Drugs Limited Announces Resignation of AnkurBisht, Company Secretary and Compliance Officer
CI
Concord Drugs Limited acquired 100% stake in Proton Remedies Private Limited for INR 14.2 million.
CI
Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023
CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
CI
Concord Drugs Limited Announces Resignation of Rakshit Sethiya as Company Secretary and Compliance Officer
CI
Concord Drugs Limited announced that it has received INR 10.364063 million in funding
CI
Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer
CI
Concord Drugs Limited announced that it expects to receive INR 10.364063 million in funding
CI
Concord Drugs Limited agreed to acquire 100% stake in Proton Remedies Private Limited.
CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022
CI
Concord Drugs Limited Announces Director Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CONCORD6 Stock
  4. News Concord Drugs Limited